Baptist Health South Florida to Acquire ZAP Surgical’s ZAP-X Gyroscopic Radiosurgery Platform for Advanced Brain Tumor Treatments

On April 27, 2022 ZAP Surgical Systems, Inc. reported that Baptist Health South Florida, will acquire the ZAP-X Gyroscopic Radiosurgery platform for cranial stereotactic radiosurgery (SRS) (Press release, ZAP Surgical Systems, APR 27, 2022, View Source [SID1234613063]). The ZAP-X will be used by Miami Neuroscience Institute, in collaboration with Miami Cancer Institute, both part of Baptist Health South Florida, dedicated to offering the most innovative and advanced techniques to diagnose and treat brain disorders and tumors. Installation of the ZAP-X platform is expected to commence in late 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As a non-invasive treatment for many primary and metastatic brain tumors, SRS is a well-established procedure that often provides equivalent to superior outcomes compared to surgery, yet requires no incision and is painless. SRS is typically delivered in one to five brief outpatient visits and patients often return to normal activity the same day as the procedure.

ZAP-X was designed to transform modern radiosurgery with a ground-breaking gyroscopic design which delivers hundreds of uniquely angled radiation beams precisely sculpted to the unique contours of targeted lesions. This novel capability aims to enhance patient outcomes by potentially improving the ability to avoid critical structures such as the brain stem, eyes, and optic nerves, while also lowering healthy brain tissue exposure to preserve patient cognitive function.

"When treating the brain, particularly with a procedure as complex as radiosurgery, the technology and precision must be exquisite," states Michael McDermott, M.D., neurosurgeon and chief medical executive of Miami Neuroscience Institute. "ZAP-X is the latest advance in SRS, and the first new dedicated radiosurgery technology platform in over 30 years. This innovation enables our center to offer patients the highest level of care."

ZAP-X is recognized for being the first and only vault-free SRS delivery system, thereby eliminating the need for providers to build costly shielded radiation treatment rooms. This unique feature also allows clinicians to remain immediately adjacent to the patient during treatment, in contrast to the long-standing practice of patients being sequestered in a shielded delivery suite during therapy.

Utilizing a modern linear accelerator to produce radiation, ZAP-X is also the first and only dedicated radiosurgery system to no longer require Cobalt-60 radioactive sources, consequently eliminating the significant efforts and costs to host, secure and regularly replace radioactive isotopes.

"Miami Cancer Institute is in the unique position of having access to virtually every radiation delivery technology available," added Dr. Minesh Mehta, M.D., deputy director and chief of radiation oncology at Miami Cancer Institute. "This allows our team to align each patient with a tailored therapy and technology for highly individualized indications and needs. We look forward to ZAP-X further complementing our portfolio of therapeutic solutions."

To facilitate rapid installation, ZAP-X will initially be located within a temporary facility and will soon migrate to the new Miami Neuroscience Institute building at Baptist Health South Florida’s Dadeland campus.

Alligator Bioscience AB Interim report January – March 2022

On April 27, 2022 Alligator Bioscience reported Interim report January – March 2022 (Presentation, Alligator Bioscience, APR 27, 2022, View Source [SID1234613079])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Abbvie and Plexium Enter Into Multi-Target Strategic Collaboration To Develop and Commercialize Targeted Protein Degradation Therapies for Neurological Conditions

April 28, 2022 Plexium, Inc. (Plexium) and AbbVie (NYSE: ABBV) reported that they have entered into an exclusive strategic collaboration to develop and commercialize novel Targeted Protein Degradation (TPD) therapeutics for neurological conditions (Press release, AbbVie, APR 27, 2022, View Source [SID1234613120]). This collaboration combines AbbVie’s extensive neuroscience capabilities with Plexium’s comprehensive TPD platform that enables the discovery of novel therapies toward historically challenging drug targets.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our partnership with AbbVie allows us to strengthen our leadership position in Targeted Protein Degradation and broaden our best-in-class capabilities into neurological diseases," said Plexium President & CEO Percival Barretto-Ko. "Neuroscience is one of the most challenging therapeutic areas to develop new drugs, due to the complexity of the disease pathologies and limited number of modalities that have been successful. With our comprehensive platform and AbbVie’s expertise in this area, we are in a strong position to discover novel degraders against multiple high-value targets to ultimately improve the lives of patients."

"Collaborating with Plexium to identify and advance novel degraders aligns with AbbVie’s efforts to use novel platform technologies to seek effective therapeutics for patients suffering from debilitating neurological diseases," said Eric Karran, Ph.D., Vice President, Neuroscience Discovery at AbbVie. "AbbVie remains focused on transformational patient impact and the promising new technologies that can accelerate the development of innovative therapies."

Under the terms of the collaboration, Plexium will conduct preclinical research activities for the collaboration targets, after which AbbVie has the option to select programs for additional research and development activities. Plexium received an upfront cash payment and is eligible to receive additional payments from AbbVie, as well as tiered royalties on commercialized products, and has the option to participate in product development in return for higher royalty rates. AbbVie will be responsible for development and commercialization globally of products resulting from the collaboration.

Lupin and Yabao Announce Strategic Partnership in China

On April 27, 2022 Global pharma major Lupin Limited (Lupin) reported that it has entered into a strategic partnership with Yabao Pharmaceutical Co. Inc. (Yabao), to meet the growing demand for quality drugs with pediatric formulations in the Chinese markets (Press release, Lupin, APR 27, 2022, View Source [SID1234613252]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The demand for high quality pediatric medicines has been growing rapidly in China as a result of the government’s support and policy measures. The latest Chinese pediatric pharmaceutical market report indicates that the market for pediatric drugs in China is expected to reach 210 billion CNY (33 billion USD) in 2021, growing at a rate of 9.23%.

Dr. Fabrice Egros, President – Corporate Development and Growth Markets, Lupin said, "We are excited about this partnership as it paves the way for us to bring quality pediatric formulations to the growing needs of patients in China. In addition to marketing our pediatric products in the Chinese market, we intend to expand our collaboration in other strategic therapeutics areas such as cardio-metabolic, central nervous system and gastro-enterology."

Mr. Wei Ren, President of Yabao said, "We are very pleased to be partnering with Lupin to further strengthen Yabao’s leadership position in the pediatric market. Yabao strives to develop its pediatric pipeline to address the urgent unmet needs in the market and to serve the pediatric patients. Moreover, Yabao also looks forward to expanding the collaboration with Lupin in other areas."

United Therapeutics Corporation to Report First Quarter 2022 Financial Results Before the Market Opens on Wednesday, May 4, 2022

On April 27, 2022 United Therapeutics Corporation (Nasdaq: UTHR) reported that it will report its first quarter 2022 financial results before the market opens on Wednesday, May 4, 2022 (Press release, United Therapeutics, APR 27, 2022, View Source [SID1234613012]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

United Therapeutics will host a public webcast Wednesday, May 4, 2022, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics’ website at View Source A rebroadcast of the webcast will be available for one week and can be accessed at the same location.